The role of an all-oral chemotherapy containing lomustine (CCNU) in advanced, fs progressive Hodgkin lymphoma: A patient-friendly palliative option which can result in longterm disease control

Annals of Oncology

Volumn 21, Issue 2, 2010, Pages 426-428

  Proctor, S J ^a   Lennard, A L ^b   Jackson, G H ^b   Jones, G L ^b   Lewis, J ^b   Wilkinson, J ^c   White, J ^a   Sieniawski, M ^a   McKay, P ^d   Culligan, D ^e   Lucraft, H H ^b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

^e ABERDEEN ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAMBUCIL; DEXAMETHASONE; ETOPOSIDE; LOMUSTINE; PREDNISOLONE; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER PALLIATIVE THERAPY; CYTOPENIA; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; GERIATRIC PATIENT; HODGKIN DISEASE; HUMAN; INSOMNIA; LEUKOPENIA; MORNING DOSAGE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; THROMBOCYTOPENIA; DISEASE COURSE; DOSE RESPONSE; EVALUATION; LETTER; MORTALITY; ORAL DRUG ADMINISTRATION; PALLIATIVE THERAPY; PATHOLOGY; PATIENT SATISFACTION; SURVIVAL; SURVIVOR; TIME;

ADMINISTRATION, ORAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHLORAMBUCIL; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; ETOPOSIDE; HODGKIN DISEASE; HUMANS; LOMUSTINE; PALLIATIVE CARE; PATIENT SATISFACTION; PREDNISOLONE; SURVIVAL ANALYSIS; SURVIVORS; TIME FACTORS;

EID: 77951936929     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp527     Document Type: Article

References (15)

1. Lennard AL, Proctor SJ, Dawson AA et al. Lomustine, vindesine and bleomycin (LVB) used in the treatment of relapsed advanced Hodgkin's disease. Hematol Oncol 1989; 7: 77-86.
2. Lennard AL, Carey PJ, Jackson GH, Proctor SJ. An effective oral combination in advanced relapsed Hodgkin's disease: prednisolone, etoposide, chlorambucil and CCNU. Cancer Chemother Pharmacol 1990; 26: 301-305.
3. Brunner KW, Maurice P, Sonntag RW. On the therapy of lymphogranuloma. CCNU (1(2-chloroethyl)3-cyclohexyl-1-nitrosourea) and BCNU (1,3-bis(2-chloroethyl)-1-nitrosourea) as well as BCNU combinations in Hodgkin's lymphogranuloma, stage 3 and 4. Schweiz Med Wochenschr 1972; 102(43): 1546-1551.
4. Young RC, Walker MD, Canellos GP et al. Initial clinical trials with methyl-CCNU 1-(2-chlorethyl)-3-(4-methyl cyclohexyl)-1-nitrosourea (MeCCNU). Cancer 1973; 31(5): 1164-1169.
5. Stolinsky DC, Solomon J, Weiner JM, Bateman JR. Results with CCNU in resistant Hodgkin's and non-Hodgkin's lymphoma. Oncology 1976; 33: 271-273.
6. Hansen HH, Selawry OS, Pajak TF et al. The superiority of CCNU in the treatment of advanced Hodgkin's disease. Cancer 1981; 47: 14-18.
7. Bonadonna G, Viviani S, Valagussa P et al. Third-line salvage chemotherapy in Hodgkin's disease. Semin Oncol 1985; 12(1) (Suppl 2): 23-25.
8. Cervantes F, Reverter JC, Montserrat E, Rozman C. Treatment of advanced resistant Hodgkin's disease with lomustine, etoposide and prednimustine. Cancer Treat Rep 1986; 70(5): 665-667.
9. Pfreundschuh MG, Schoppe WD, Fuchs R et al. Lomustine, etoposide, vindesine and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine and prednisone (COPP) and doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD): a multicenter trial of the German Hodgkin Study Group. Cancer Treat Rep 1987; 71(12): 1203-1207.
10. Szanto I, Fleischmann T, Eckhardt S. Treatment of resistant Hodgkin's disease with CCNU, etoposide and prednimustine (CEP). Oncology 1991; 48(6): 456-458.
11. Zinzani PL, Barbieri E, Bendandi M et al. CEP regimen (CCNU, etoposide, prednimustine) for relapsed/refractory Hodgkin's disease. Tumori 1994; 80(6): 438-442.
12. Brusamolino E, Orlandi E, Canevari A et al. Results of CAV regimen (CCNU, melphalan and VP-16) as third-line salvage therapy for Hodgkin's disease. Ann Oncol 1994; 5(5): 427-432.
13. Wiernik PH, Dutcher JP, Einzig AI et al. Mitoxantrone, vinblastine, and lomustine (CCNU) (MCV): a highly active regimen for advanced and poor-prognosis Hodgkin's disease. Cancer J Sci Am 1998; 4(4): 254-260.
14. Alexandrescu DT, Karri S, Wiernik PH, Dutcher JP. Mitoxantrone, vinblastine and CCNU: long-term follow-up of patients treated for advanced and poor-prognosis Hodgkin's disease. Leuk Lymphoma 2006; 47(4): 641-656.
15. Proctor SJ, Wilkinson J, Sieniawski M. Hodgkin lymphoma in the elderly: a clinical review of treatment and outcome, past present and future. Crit Rev Oncol Hematol 2009; 71: 222-232.